NASDAQ:CRDF Cardiff Oncology (CRDF) Stock Forecast, Price & News $1.66 +0.04 (+2.47%) (As of 05/26/2023 04:00 PM ET) Add Compare Share Share Today's Range$1.58▼$1.6850-Day Range$1.37▼$1.9552-Week Range$1.17▼$3.41Volume126,600 shsAverage Volume216,449 shsMarket Capitalization$74.17 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Cardiff Oncology MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside381.9% Upside$8.00 Price TargetShort InterestHealthy1.21% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.09) to ($1.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.20 out of 5 starsMedical Sector416th out of 1,010 stocksBiological Products, Except Diagnostic Industry61st out of 169 stocks 3.5 Analyst's Opinion Consensus RatingCardiff Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, Cardiff Oncology has a forecasted upside of 381.9% from its current price of $1.66.Amount of Analyst CoverageCardiff Oncology has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.21% of the outstanding shares of Cardiff Oncology have been sold short.Short Interest Ratio / Days to CoverCardiff Oncology has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cardiff Oncology has recently decreased by 12.09%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCardiff Oncology does not currently pay a dividend.Dividend GrowthCardiff Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRDF. Previous Next 3.0 News and Social Media Coverage News SentimentCardiff Oncology has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cardiff Oncology this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for CRDF on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cardiff Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.50% of the stock of Cardiff Oncology is held by insiders.Percentage Held by InstitutionsOnly 17.75% of the stock of Cardiff Oncology is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cardiff Oncology are expected to decrease in the coming year, from ($1.09) to ($1.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cardiff Oncology is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cardiff Oncology is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCardiff Oncology has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cardiff Oncology (NASDAQ:CRDF) StockCardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.Read More Receive CRDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address CRDF Stock News HeadlinesMay 13, 2023 | americanbankingnews.comHC Wainwright Analysts Decrease Earnings Estimates for Cardiff Oncology, Inc. (NASDAQ:CRDF)May 11, 2023 | americanbankingnews.comHC Wainwright Lowers Cardiff Oncology (NASDAQ:CRDF) Price Target to $14.00May 29, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 9, 2023 | msn.comHC Wainwright & Co. Maintains Cardiff Oncology (CRDF) Buy RecommendationMay 5, 2023 | finanznachrichten.deCardiff Oncology, Inc.: Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business UpdateMay 4, 2023 | finance.yahoo.comCardiff Oncology Reports First-Quarter 2023 Results and Provides Business UpdateApril 5, 2023 | americanbankingnews.comHead to Head Comparison: Cardiff Oncology (NASDAQ:CRDF) versus Advanced Life Sciences (OTCMKTS:ADLS)April 2, 2023 | dailymail.co.ukCardiff CityMay 29, 2023 | Investor Place Media (Ad)Disturbing Truth About Biden's New Program To Seize Your CashA former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.April 2, 2023 | bbc.co.ukEuropean Challenge Cup: Cardiff v Sale (Sat)March 31, 2023 | americanbankingnews.comCardiff Oncology (NASDAQ:CRDF) Rating Reiterated by HC WainwrightMarch 28, 2023 | finance.yahoo.comCardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with Metastatic Colorectal CancerMarch 13, 2023 | 247wallst.comUnusual Put Option Trade in Cardiff Oncology Worth $52.5KMarch 10, 2023 | nasdaq.comUnusual Put Option Trade in Cardiff Oncology (CRDF) Worth $52.50KMarch 6, 2023 | finance.yahoo.comCardiff Oncology Formally Introduces Scientific Advisory BoardMarch 4, 2023 | finance.yahoo.comCardiff Oncology Full Year 2022 Earnings: Beats ExpectationsMarch 3, 2023 | finanznachrichten.deCardiff Oncology, Inc.: Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business UpdateMarch 3, 2023 | msn.comCardiff Oncology GAAP EPS of -$0.89 beats by $0.05, revenue of $0.39M beats by $0.12MMarch 3, 2023 | finance.yahoo.comCardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business UpdateFebruary 27, 2023 | finance.yahoo.comCardiff Oncology to Present at the Cowen 43rd Annual Health Care ConferenceFebruary 2, 2023 | finance.yahoo.comCardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical OfficerJanuary 29, 2023 | bbc.co.ukSabri Lamouchi: Cardiff City appoint third manager of seasonJanuary 28, 2023 | uk.news.yahoo.comChampionship side Cardiff hire Lamouchi as new bossJanuary 28, 2023 | dailymail.co.ukCardiff director Hayley Parsons says Welsh Rugby is 'fundamentally broken from top to bottom' after allegations of sexism and misogyny... as she adds to calls for WRU chief ...January 28, 2023 | nasdaq.comAcorn Bioventures, L.p. Cuts Stake in Cardiff Oncology Inc (CRDF)January 16, 2023 | bbc.co.ukEuropean Challenge Cup: Cardiff 42-10 Newcastle Falcons - hosts reach last 16 after red cardJanuary 12, 2023 | bbc.co.ukEmiliano Sala: Cardiff City pay Nantes first instalment of transfer feeSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CRDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address CRDF Company Calendar Last Earnings5/04/2023Today5/29/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRDF CUSIPN/A CIK1213037 Webcardiffoncology.com Phone(858) 952-7570FaxN/AEmployees22Year Founded1999Price Target and Rating Average Stock Price Forecast$8.00 High Stock Price Forecast$14.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+381.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,700,000.00 Net Margins-9,862.78% Pretax Margin-9,856.71% Return on Equity-35.70% Return on Assets-32.63% Debt Debt-to-Equity RatioN/A Current Ratio12.49 Quick Ratio12.49 Sales & Book Value Annual Sales$390,000.00 Price / Sales190.18 Cash FlowN/A Price / Cash FlowN/A Book Value$2.16 per share Price / Book0.77Miscellaneous Outstanding Shares44,680,000Free Float43,113,000Market Cap$74.17 million OptionableNot Optionable Beta1.74 Social Links Key ExecutivesMark ErlanderChief Executive Officer & DirectorVicki KelemenChief Operating OfficerJames E. LevineChief Financial OfficerTod SmealChief Scientific OfficerFairooz KabbinavarChief Medical OfficerKey CompetitorsIN8bioNASDAQ:INABElevation OncologyNASDAQ:ELEVMiNK TherapeuticsNASDAQ:INKTInstil BioNASDAQ:TILCurisNASDAQ:CRISView All CompetitorsInsiders & InstitutionsSusquehanna International Group LLPBought 42,100 shares on 5/16/2023Ownership: 0.000%Two Sigma Advisers LPSold 43,400 shares on 5/15/2023Ownership: 0.321%Two Sigma Investments LPBought 6,691 shares on 5/15/2023Ownership: 0.067%Belvedere Trading LLCSold 12,800 shares on 5/15/2023Ownership: 0.000%BlackRock Inc.Bought 7,972 shares on 5/12/2023Ownership: 1.696%View All Insider TransactionsView All Institutional Transactions CRDF Stock - Frequently Asked Questions Should I buy or sell Cardiff Oncology stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiff Oncology in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRDF shares. View CRDF analyst ratings or view top-rated stocks. What is Cardiff Oncology's stock price forecast for 2023? 3 Wall Street research analysts have issued 12 month price targets for Cardiff Oncology's shares. Their CRDF share price forecasts range from $5.00 to $14.00. On average, they expect the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 381.9% from the stock's current price. View analysts price targets for CRDF or view top-rated stocks among Wall Street analysts. How have CRDF shares performed in 2023? Cardiff Oncology's stock was trading at $1.40 on January 1st, 2023. Since then, CRDF shares have increased by 18.6% and is now trading at $1.66. View the best growth stocks for 2023 here. Are investors shorting Cardiff Oncology? Cardiff Oncology saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 542,300 shares, a decline of 12.1% from the April 30th total of 616,900 shares. Based on an average daily volume of 198,500 shares, the short-interest ratio is currently 2.7 days. View Cardiff Oncology's Short Interest. When is Cardiff Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our CRDF earnings forecast. How were Cardiff Oncology's earnings last quarter? Cardiff Oncology, Inc. (NASDAQ:CRDF) posted its quarterly earnings results on Thursday, May, 4th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.02. The business had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.08 million. Cardiff Oncology had a negative net margin of 9,862.78% and a negative trailing twelve-month return on equity of 35.70%. What other stocks do shareholders of Cardiff Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiff Oncology investors own include Sorrento Therapeutics (SRNE), Livongo Health (LVGO), Co-Diagnostics (CODX), Novavax (NVAX), Fortress Biotech (FBIO), Maxar Technologies (MAXR), Ontrak (OTRK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX) and Cassava Sciences (SAVA). What is Cardiff Oncology's stock symbol? Cardiff Oncology trades on the NASDAQ under the ticker symbol "CRDF." Who are Cardiff Oncology's major shareholders? Cardiff Oncology's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.70%), Citigroup Inc. (1.46%), Assenagon Asset Management S.A. (0.88%), Renaissance Technologies LLC (0.74%), Two Sigma Advisers LP (0.32%) and Blair William & Co. IL (0.29%). Insiders that own company stock include Gary W Pace, James E Levine, John P Brancaccio, Lale White, Mark Erlander, Renee P Tannenbaum, Rodney S Markin and Vicki Kelemen. View institutional ownership trends. How do I buy shares of Cardiff Oncology? Shares of CRDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cardiff Oncology's stock price today? One share of CRDF stock can currently be purchased for approximately $1.66. How much money does Cardiff Oncology make? Cardiff Oncology (NASDAQ:CRDF) has a market capitalization of $74.17 million and generates $390,000.00 in revenue each year. The company earns $-38,700,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. How can I contact Cardiff Oncology? Cardiff Oncology's mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The official website for the company is cardiffoncology.com. The company can be reached via phone at (858) 952-7570 or via email at ir@cardiffoncology.com. This page (NASDAQ:CRDF) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.